Coal in Europe production. According to IEA the coal based emissions in 1971–2008 were 303,262 Mt worldwide, 58,210 Mt (19.2%) in OECD Europe, and 5,086 Mt (1.7%) in non-OECD Europe. Europe here excludes European Russia and all the ex-Soviet states. The estimated external costs of coal carbon emissions in 2007 were €69 billion in OECD Europe and €6 billion in non-OECD Europe. The coal mining industry also has occupational hazards. In the Komi Republic, Russia, at the centre of the mining industry, occupational diseases are five time more prevalent than in the rest of the Russian Federation. Accidents are also known to happen
MT-45 States the DEA placed MT-45 in Schedule 1 of the Controlled Substance Act. This took effect January 12, 2018. MT-45 MT-45 (IC-6) is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-(1,2-diphenylethyl)piperazine derivative, which is structurally unrelated to most other opioid drugs. Racemic MT-45 has around 80% the potency of morphine, with almost all opioid activity residing in the (S) enantiomer (the opposite stereochemistry from the related drug lefetamine). It has been used as a lead compound from which a large family of potent opioid drugs have been developed, including full agonists,